Feature | April 02, 2009

McKesson Releases Molecular Diagnostics Criteria Upgrade

April 2, 2009 - McKesson’s releases its 2009 InterQual Criteria and CareEnhance Review Manager 8.0 software features industry-leading innovations including molecular and genetic diagnostics criteria.

The new criteria, combined with the option for clients to access it via McKesson’s recently launched auto authorization capability, is designed to increase the value of the content for users while helping improve quality of care for patients.

“As we bring the latest versions of our criteria and software to market, we are focused on driving efficiencies for payors and providers while expanding into new content areas,” said Tammie Phillips, vice president of InterQual for McKesson Health Solutions. “Even as we address major industry issues with our new auto authorization functionality and molecular diagnostics content, we continue to enhance and add value to the existing elements of our solution suite that have made it the gold standard in evidence-based clinical decision support.”

McKesson’s auto authorization is a hosted, Web-based offering that leverages McKesson’s new Advanced Diagnostics Management solution. The offering automates the entire authorization process, from the initial request all the way through final authorization. McKesson’s auto authorization capability can incorporate InterQual Molecular Diagnostics Criteria and select Imaging Criteria—and soon selected Procedures Criteria—so that medical appropriateness is determined automatically for most requests. The content plus technology drive reduced administrative costs, better payor-provider relations and support optimal care.

The new InterQual Molecular Diagnostics Criteria is an important innovation included in this release. McKesson provides a comprehensive set of criteria to support decision-making for molecular diagnostic tests.

Molecular Diagnostics Criteria is updated quarterly so it is always current. To help healthcare organizations determine test appropriateness based on clinical evidence, InterQual Molecular Diagnostics Criteria covers over 225 tests that comprise approximately 85 percent of the costs in this growing area. A new question and answer format leads to service recommendations that include alternative and concurrent tests, allowing users to easily conduct reviews and act on information. In addition, pop-up notes and clinical evidence summaries drive evidence-based medicine to the point of decision-making with more efficiency. The content is available in CareEnhance Review Manager software as well as McKesson’s Advanced Diagnostics Management solution auto authorization capability.

For more information: www.mckesson.com

Related Content

National Clinical Decision Support Company (NDSC) has an exclusive deal with the American College of Radiology (ACR) to provide medical imaging appropriate use criteria (AUC).

National Clinical Decision Support Company (NDSC) has an exclusive deal with the American College of Radiology (ACR) to provide medical imaging appropriate use criteria (AUC). 

Feature | Clinical Decision Support | January 18, 2018
January 18, 2018 — Change Healthcare announced the acquisition of National Decision Support Company (NDSC), a leader
News | Clinical Decision Support | January 12, 2018
January 12, 2018 — GE Healthcare has entered into a strategic, long-term partnership with Roche to jointly develop an
ACR Appropriateness Criteria Adds and Revises Topics for December 2017
News | Clinical Decision Support | December 29, 2017
December 29, 2017 — Radiologists can enhance the quality and effectiveness of care with the newest release of the ACR
Mirada Medical and Optellum Debut AI-Based Lung Cancer Diagnosis Solution at RSNA 2017
News | Computed Tomography (CT) | December 14, 2017
Optellum, a high-tech startup in lung cancer and machine learning, and Mirada Medical recently announced a partnership...
HealthMyne Highlights Value of Quantitative Data in Oncology Reads at RSNA 2017
News | Clinical Decision Support | November 17, 2017
November 17, 2017 — At the 2017 Radiological Society of North America (RSNA) conference, HealthMyne will demonstrate
Intelerad Announces Partnership With MedCurrent
News | Clinical Decision Support | November 13, 2017
November 13, 2017 — Intelerad Medical Systems announced a partnership that will see MedCurrent’s OrderWise...
Netherlands Cancer Institute Exploring Molecular Imaging Technology for Prostate Cancer Surgery
News | Molecular Imaging | October 26, 2017
The Netherlands Cancer Institute (NKI) announced it has received funding from the Dutch Cancer Society (KWF...
SNMMI Publishes New FDG PET/CT Appropriate Use Criteria
News | PET-CT | October 25, 2017
The Society of Nuclear Medicine and Molecular Imaging (SNMMI) has published appropriate use criteria (AUC) for FDG PET/...
HealthMyne QIDS 3.0 Platform Addresses Incidental Findings Workflow
Technology | PACS Accessories | October 18, 2017
October 18, 2017 — HealthMyne announced the release of QIDS (Quantitative Imaging Decision Support) 3.0 with the Inci
Appropriate Use Criteria Published for Valvular Heart Disease Imaging Tests
News | Clinical Decision Support | October 16, 2017
The American College of Cardiology (ACC), along with several partnering societies, recently released appropriate use...
Overlay Init